Abstract:Transthyretin (TTR) is a major amyloidogenic protein associated with hereditary (ATTRm) and nonhereditary (ATTRwt) intractable systemic transthyretin amyloidosis. The pathological mechanisms of ATTR-associated amyloid fibril formation are incompletely understood, and there is a need for identifying compounds that target ATTR. C-terminal TTR fragments are often present in amyloid-laden tissues of most patients with ATTR amyloidosis, and on the basis of in vitro studies, these fragments have been proposed to play important roles in amyloid formation. Here, we found that experimentally-formed aggregates of full-length TTR are cleaved into C-terminal fragments, which were also identified in patients' amyloid-laden tissues and in SH-SY5Y neuronal and U87MG glial cells. We observed that a 5-kDa C-terminal fragment of TTR, TTR81-127, is highly amyloidogenic in vitro, even at neutral pH. This fragment formed amyloid deposits and induced apoptosis and inflammatory gene expression also in cultured cells. Using the highly amyloidogenic TTR81-127 fragment, we developed a cell-based high-throughput screening method to discover compounds that disrupt TTR amyloid fibrils. Screening a library of 1280 off-patent drugs, we identified two candidate repositioning drugs, pyrvinium pamoate and apomorphine hydrochloride. Both drugs disrupted patient-derived TTR amyloid fibrils ex vivo, and pyrvinium pamoate also stabilized the tetrameric structure of TTR ex vivo in patient plasma. We conclude that our TTR81-127-based screening method is very useful for discovering therapeutic drugs that directly disrupt amyloid fibrils. We propose that repositioning pyrvinium pamoate and apomorphine hydrochloride as TTR amyloid-disrupting agents may enable evaluation of their clinical utility for managing ATTR amyloidosis.

Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds

Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors

The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?

Resveratrol Derivatives Inhibit Transthyretin Fibrillization: Structural Insights into the Interactions between Resveratrol Derivatives and Transthyretin

A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors

Novel Strategy To Inhibit Transthyretin Amyloidosis via the Synergetic Effect of Chemoselective Acylation and Noncovalent Inhibitor Release

Inhibitors of Transthyretin Amyloidosis: How to Rank Drug Candidates Using X-ray Crystallography Data

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells

Transthyretin mutagenesis: impact on amyloidogenesis and disease

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation

Small molecule amyloid disrupters demonstrate therapeutic efficacy for transthyretin amyloidosis

Cationic Surface Charge Engineering of Recombinant Transthyretin Remarkably Increases the Inhibitory Potency Against Amyloid β-Protein Fibrillogenesis

Structure restoration and aggregate inhibition of V30M mutant transthyretin protein by potential quinoline molecules

Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis

Tetrameric Transthyretin as a Protective Factor Against Alzheimer's Disease

Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation

Kinetics of Inhibition of Β-Amyloid Aggregation by Transthyretin